43rd week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210330624 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES AND/OR DISORDERS CAUSED BY EXPOSURE TO AIR POLLUTION - In various embodiments, the present disclosure provides compositions and methods for treating and/or preventing diseases and disorders caused by exposure to air pollution and/or inhalation of particulate matter, such as oxidative stress, endothelial dysfunction, narrowing and/or thickening of arteries, and/or inflammation. | 2021-10-28 |
20210330625 | LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS - Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions containing defined ratios of 5,11,14-eicosatrienoic acid to one or more of: 5, 9, 12-octadecatrienoic acid; 7, 11, 14-eicosatrienoic acid; 5, 8, 11, 14-eicosatetraenoic acid; 9, 12-octadecadienoic acid; 9-octadecenoic acid; 14-methylhexadecanoic acid; 11, 14 eicosadienoic acid, 5, 9-octadecadienoic acid; 5, 11-octadecadienoic acid; 9, 12, 15-octadecatrienoic acid; 5,8,11,14,17-eicosapentaenoic acid; 7,10,13,16,19-docosapentaenoic acid; and 4,7,10,13,16,19-docosahexaenoic acid. | 2021-10-28 |
20210330626 | PHARMACEUTICAL COMPOSITION FOR TREATING KIDNEY CANCER AND APPLICATION THEREOF - A pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects. | 2021-10-28 |
20210330627 | METHOD OF USING A CHLOROGENIC ACID COMPOSITION FOR SUPPORTING COGNITIVE FUNCTION - The invention provides compositions comprising chlorogenic acid and methods for their use and manufacture in the treatment of Alzheimer's disease. The compositions can be formulated from botanical sources of chlorogenic acid including sunflower seed extract. | 2021-10-28 |
20210330628 | Pharmaceutical Compositions Comprising Dimethyl Fumarate - Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastro-resistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders. | 2021-10-28 |
20210330629 | METHODS FOR TREATING MITOCHONDRIAL DISORDERS - The present disclosure provides pharmaceutical and nutraceutical compositions and methods for the treatment of mitochondrial disorders. The pharmaceutical or nutraceutical compositions include a stabilized sulforaphene, such as sulforaphene-cyclodextrin complex, that increases the efficacy, biological activity and stability of isolated sulforaphene. The present disclosure also includes the use of stabilized sulforaphene as an effective therapeutic agent for the treatment of mitochondrial disorders, such as mitochondrial myopathy. | 2021-10-28 |
20210330630 | RIVASTIGMINE PATCH FOR LONG-TERM ADMINISTRATION - The present invention relates to a patch comprising a high content of rivastigmine per unit area, which can be continuously administered for a long time. The rivastigmine patch according to the present invention is capable of continuous release of rivastigmine for a long period of time, preferably 3 days, more preferably 4 days or more after attachment, and has excellent physical and chemical stability. | 2021-10-28 |
20210330631 | FORMULATION OF CALCIUM CHANNEL BLOCKERS FOR TREATMENT OF SARS-COV-2 INDUCED COVID-19 AND OTHER RESPIRATORY VIRUSES THROUGH PULMONARY DELIVERY - The invention relates to a formulation of Calcium Channel Blocker (CCB) through pulmonary delivery using an inhaler, nebulizer or a similar delivery system against a novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induced COVID-19 and other respiratory viruses such as influenza, SARS, MERS etc. The formulation comprises verapamil hydrochloride at a concentration between 15 mg/mL and 25 mg/mL, sodium chloride at a concentration of 6.25 mg/mL and distilled water at a volume between q.s. to 1 mL. The formulation is administered as pulmonary delivery through nasal spray. The calcium signaling plays an important role in entry and replication of virus in the host cell and hence targeting the calcium channels or pumps that mediate the mobility of the intracellular calcium is an effective target for SARS-CoV-2 infection. | 2021-10-28 |
20210330632 | METHODS FOR TREATING OBESITY - The present invention relates to methods of treating overweight or obesity, reducing fat, sugar, and food intake, and reducing body weight or body weight gain in a subject using geranium oil or orlistat mouthwash, or a combination of both. | 2021-10-28 |
20210330633 | METHODS FOR TREATING GAUCHER DISEASE - Methods for treating Gaucher disease in patients with renal or hepatic impairment. | 2021-10-28 |
20210330634 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 2021-10-28 |
20210330635 | THERAPEUTIC COMPOSITIONS, PRODUCTS OF MANUFACTURE AND METHODS FOR AMELIORATING OR PREVENTING CORONAVIRUS INFECTION - In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™) and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder. | 2021-10-28 |
20210330636 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY - The present disclosure relates to the use of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Lennox-Gastaut syndrome; Dravet syndrome; or Acardi syndrome. | 2021-10-28 |
20210330637 | CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT - A formulation for pain management is provided comprising cannabichromene as the primary cannabinoid together with an excipient and, optionally, one or more secondary cannabinoids in an amount of up to 5% by weight of the primary cannabinoid. The formulation is essentially free of tetrahydrocannabinol. The types of pain to be managed with the formulation include but are not limited to the treatment of neuropathic pain, pain due to cancer, injury, accident, surgery, or tissue damage. Methods of use of the formulation, doses and dosage forms are described. | 2021-10-28 |
20210330638 | NANO-PENETRATIVE CANNABINOID OIL BLENDS AND COMPOSITIONS AND METHODS OF FORMULATION THEREOF - The present disclosure relates to methods of formulating therapeutic oil blends comprising one or more terpenes, wherein the methods may result in blends exhibiting increased stability and bioavailability. The methods may be used to produce compositions for dermal or transdermal application useful in the treatment of, e.g., pain. Disclosed methods may also result in improved homogeneity and non-crystallization of the formulated products. | 2021-10-28 |
20210330639 | USE OF MONASCINOL IN PREPARATION OF FAT-REDUCING PRODUCT - The present application provides use of Monascinol in preparation of a fat-reducing product, a method for preventing or treating a disease related to abnormal lipid metabolism, and a fat-reducing product including Monascinol. The fat-reducing product includes a fat-reducing functional food and a fat-reducing drug, the fat-reducing functional food is used for preventing or improving a sub-health state related to obesity in an individual, the fat-reducing drug is used for preventing or treating a disease related to abnormal lipid metabolism in an individual. It is found that in the solution of the present application the Monascinol has new functions of significantly lowering blood lipid, controlling weight gain, and inhibiting body fat accumulation; and has low cytotoxicity, thereby having high use safety when serving as a fat-reducing product. | 2021-10-28 |
20210330640 | GALLOYLATED PROCYANIDINS FOR INCREASING INTRACELLULAR NITRIC OXIDE PRODUCTION - A composition, workout/exercise supplement, treatment method for conditions associated with vasoconstriction, and method of extracting galloylated procyanidins. The composition includes galloylated procyanidins having a preponderance of (−)-epicatechins. The treatment methods include administering a therapeutically effective amount of galloylated procyanidins having a preponderance of (−)-epicatechins. The extraction methods include isolating galloylated procyanidins having a preponderance of (−)-epicatechins from a sample that contains polyphenols, catechins, epicatechins, and galloylated epicatechins. | 2021-10-28 |
20210330641 | Pharmaceutical Preparations - Pharmaceutical preparations are proposed, comprising bitter-masking acting substances for reducing and/or inhibiting gastric acid secretion induced by food constituents. | 2021-10-28 |
20210330642 | METHOD FOR TREATING CANCER BY COMBINATION OF IAP INHIBITOR AND MODULATOR OF IMMUNE CHECKPOINT MOLECULE - The present disclosure pertains to the field of biomedicine, and specifically relates to a method for treating, suppressing, reducing the severity of, lowering the risk of, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and optionally a therapeutically effective amount of a tubulin inhibitor. The present disclosure further relates to a pharmaceutical composition or kit comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, and optionally a tubulin inhibitor. | 2021-10-28 |
20210330643 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TR- IFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE - A spray-dried dispersions and pharmaceutical composition of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the spray-dried dispersion and pharmaceutical composition in the treatment of cancer and autoimmune and inflammatory diseases are disclosed. Also provided are crystalline forms of (S)-5-amino-3-(4-((5-fluoro-2-methoxy-benzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide also useful in the treatment of cancer and autoimmune and inflammatory diseases. | 2021-10-28 |
20210330644 | COMBINATION THERAPY FOR TREATING METASTATIC PROSTATE CANCER - Provided herein are compositions and related methods for treating and/or identifying patients likely to respond to treatments for prostate cancer. | 2021-10-28 |
20210330645 | ANTIBACTERIAL COMBINATIONS - Disclosed herein are antibacterial combinations and compositions that are effective against Gram-negative bacteria. Also disclosed are uses of such combinations and compositions for inhibiting the growth and proliferation of Gram-negative bacteria and/or for killing Gram-negative bacteria and/or for treating a Gram-negative bacterial infection. | 2021-10-28 |
20210330646 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS - In some embodiments, a method of promoting spinogenesis in a patient is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound which binds to fascin at least at binding site 2 or binding site 3. | 2021-10-28 |
20210330647 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE - The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay. | 2021-10-28 |
20210330648 | Pharmaceutical composition and use thereof - Disclosed is a pharmaceutical composition comprising: an active ingredient of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof present in an amount of 8 wt % to 30 wt %: | 2021-10-28 |
20210330649 | COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ACUTE RENAL INJURY - Pharmaceutical compositions are provided for the treatment, pre-emptive treatment or prevention of acute renal injury. | 2021-10-28 |
20210330650 | SPIROCHROMANE DERIVATIVES - The invention relates to spirochromane derivatives, or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof, as well as to pharmaceutical compositions containing them and to their use as modulators of α7 nicotinic acetylcholine receptor activity in a mammalian subject. | 2021-10-28 |
20210330651 | ESTROGEN RECEPTOR MODULATORS - Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer. | 2021-10-28 |
20210330652 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF - Methods of treatment of addiction and/or dependence, methods of promoting cessation of various addictions, such as smoking and/or vaping, and methods of promoting a reduction in various addictions, such as smoking and/or vaping, uses of cytisine as an addiction cessation treatment, and dosage regimens for the foregoing are provided. | 2021-10-28 |
20210330653 | Dosage Regimen for the Treatment of Cancer - The present specification relates to AZD9833 for use in the treatment of cancer and methods of treatment of cancer involving administration of AZD9833 wherein, in each case, the AZD9833 is administered orally once daily at a dose between 25 mg and 450 mg. AZD9833 may be administered alone or its use may be in combination with an additional anti-cancer agent such as a CDK inhibitor, everolimus or an AKT inhibitor. | 2021-10-28 |
20210330654 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG - A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded. | 2021-10-28 |
20210330655 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT AND PREVENTION OF AVIAN PATHOGENIC E. COLI (APEC) - Disclosed are anti-avian pathogenic | 2021-10-28 |
20210330656 | METHOD OF TREATMENT WITH TRADIPITANT - Disclosed herein is a method of treatment of gastric motility disorders and of improving gastric motility comprising treatment with the NK-1 receptor antagonist, tradipitant. | 2021-10-28 |
20210330657 | EXTENDED RELEASE COMPOSITIONS COMPRISING TRIHEXYPHENIDYL - The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide extended release of trihexyphenidyl hydrochloride, with reduced C | 2021-10-28 |
20210330658 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION - The present invention relates to agonists of the 5-HT | 2021-10-28 |
20210330659 | USE OF NICOTINAMIDE COMPOSITION IN PREPARATION OF DRUG FOR TREATING HAND-FOOT SKIN REACTION INDUCED BY SORAFENIB - The present disclosure provides a use of a nicotinamide composition in preparation of a drug for treating hand-foot skin reaction (HFSR) induced by sorafenib, the composition being consisted of nicotinamide and sorafenib in a dosage ratio of 2:3. The composition provided by the present disclosure can alleviate the HFSR caused by excessive keratinization induced by sorafenib. This protective effect is achieved by inhibiting HB-EGF/SIRT1 pathway. The present disclosure provides a mechanism of sorafenib-induced HFSR, i.e., the excessive activation of the HB-EGF/SIRT1 pathway, thereby providing a theoretical foundation for clinical research of sorafenib-induced HFSR. The present disclosure also provides a drug that can effectively treat sorafenib-induced HFSR, thereby greatly broadening the clinical application of sorafenib. Nicotinamide is highly clinically feasible due to its moderate price, and thus can be prepared in any suitable formulation according to the requirements. | 2021-10-28 |
20210330660 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS - The instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists. The CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache. | 2021-10-28 |
20210330661 | Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof - The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (M | 2021-10-28 |
20210330662 | QUINOLYLNITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA - The invention relates to neuroprotective, antioxidant quinolylnitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer's and Parkinson's disease and amyotrophic lateral sclerosis. | 2021-10-28 |
20210330663 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, PREVENTING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION - In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (e.g., PLAQUENIL™), wherein optionally each or both of the opaganib and the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (e.g., PLAQUENIL™) are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, liquid or powder. | 2021-10-28 |
20210330664 | PHARMACEUTICAL COMPOSITIONS - The present disclosure relates to new crystal forms of chemical compounds, formulations including, methods of forming, and methods of using same. | 2021-10-28 |
20210330665 | PHARMACEUTICAL FORMULATIONS - The present specification relates to pharmaceutical formulations comprising N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA), for example tablets with immediate release properties. | 2021-10-28 |
20210330666 | ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARING THE SAME - An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent. A method of preparing an oral solid formulation includes forming granules containing irinotecan or a pharmaceutically acceptable salt thereof, a diluent, and a binder, mixing the granules with a disintegrant and a lubricant to obtain a mixture, and includes adding an acidifying agent in step of forming granules and/or mixing the granules. | 2021-10-28 |
20210330667 | TOPICAL COMPOSITION OF NALBUPHINE AND METHOD FOR TREATING PRURITUS CONDITION, PAIN, OR INFLAMMATORY CONDITION BY USING THE SAME - Provided is a topical composition of nalbuphine, comprising nalbuphine or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient comprising a penetration enhancer, a thickening agent, a solvent, or any combination thereof. Also provided are a kit comprising a unit dosage of the topical composition of nalbuphine and a method treating pruritus condition, pain, or inflammatory condition by using the topical composition of nalbuphine. | 2021-10-28 |
20210330668 | TREATMENT OF JOINT CONDITIONS - The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin. | 2021-10-28 |
20210330669 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROSI INHIBITOR AND EGFR INHIBITOR - The present invention pertains to the biomedical field, and particularly relates to a method for treating or suppressing a cancer, reducing its severity, lowering its risk or inhibiting its metastasis in an individual. The method comprises administering to the individual a therapeutically effective amount of one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and a therapeutically effective amount of an EGFR inhibitor. The invention also relates to a pharmaceutical composition or kit comprising one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and an EGFR inhibitor. | 2021-10-28 |
20210330670 | COUMARIN DERIVATIVE FOR THERAPY OR PROPHYLAXIS OF A CELL PROLIFERATIVE DISORDER - The present invention provides a medicament for the treatment or prevention of a cell proliferative disorder, the medicament comprising as an active ingredient a compound represented by formula or a pharmaceutically acceptable salt thereof, wherein the medicament is used in such a manner that: (a) said compound or salt is administered twice weekly for 3 weeks, (b) administration of said compound or salt is paused for the following 1 week, and (c) steps (a) and (b) are subsequently repeated at least once. | 2021-10-28 |
20210330671 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS - This invention is directed to a compound of formula (1): | 2021-10-28 |
20210330672 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES - Described herein include compositions and methods that can be useful for inhibiting activity of Tfh cells, B-cells, germinal centers, extrafollicular T and B-cells, and/or ectopic follicular structures; and/or in treating diseases such as autoimmune diseases. | 2021-10-28 |
20210330673 | MULTI-KINASE INHIBITORS OF VEGF AND TGF BETA AND USES THEREOF - A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib. | 2021-10-28 |
20210330674 | DEUTERATED DERIVATIVES OF RUXOLITINIB - The present invention in one embodiment provides a compound of Formula A: | 2021-10-28 |
20210330675 | METHODS OF TREATING LIVER DISORDERS OR LIPID DISORDERS WITH A THR-BETA AGONIST - The present invention provides a method for treating a liver disorder or lipid disorder in a subject in need thereof with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, a stereoisomer, a salt thereof, or a morphic form thereof. | 2021-10-28 |
20210330676 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS - Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. | 2021-10-28 |
20210330677 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH CTM TARGETING - The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle. | 2021-10-28 |
20210330678 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF - The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof. | 2021-10-28 |
20210330679 | PLATINUM-ACRIDINE COMPOUNDS AND METHODS OF TREATING CANCERS - Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter. | 2021-10-28 |
20210330680 | HYPOTENSIVE LIPID-CONTAINING BIODEGRADABLE INTRAOCULAR IMPLANTS AND RELATED IMPLANTS - Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 2021-10-28 |
20210330681 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS - Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same. | 2021-10-28 |
20210330682 | COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC AGENTS INTO THE COLON - Enema compositions containing corticosteroids or salicylic acid derivatives are disclosed. The compositions are liquid at room temperature but turn to gels at body temperature. They are useful for treating inflammatory bowel disease. | 2021-10-28 |
20210330683 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF ANTIVIRAL AGENTS - Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents. | 2021-10-28 |
20210330684 | AZD3355 (LESOGABERAN) FOR TREATMENT AND PREVENTION OF NONALCOHOLIC STEATOHEPATITIS (NASH), LIVER FIBROSIS, AND OTHER LIVER CONDITIONS - The present invention relates to methods of treatment or prevention of fatty liver disease, nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis, hepatocellular carcinoma and related liver disease and conditions by administering an effective amount of a GABA | 2021-10-28 |
20210330685 | INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS - The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation. | 2021-10-28 |
20210330686 | COMPOSITION CONTAINING 2'-FUCOSYLLACTOSE FOR PREVENTING STROKE - Disclosed is a food or pharmaceutical composition containing 2′-fucosyllactose (2′-FL) for preventing a stroke. The food or pharmaceutical composition containing 2′-fucosyllactose (2′-FL) is highly effective in preventing a stroke. | 2021-10-28 |
20210330687 | BIFIDOGENIC HYPOALLERGENIC GOS COMPOSITIONS AND METHODS FOR PROVIDING THE SAME INVOLVING BETA-GALACTOSIDASE FROM A STRAIN OF LACTOBACILLUS DELBRUECKII SSP BULGARICUS - The invention relates to the field of hypoallergenic oligosaccharides for use in nutritional compositions, in particular to oligosaccharides having prebiotic properties. Provided is a hypoallergenic oligosaccharide composition comprising galacto-oligosaccharides (GOS), wherein (i) the galacto-oligosaccharides (GOS) content is at least 40% by weight of the total dry matter of the composition; (ii) the allolactose content is at least 10% by weight of the total dry matter of the composition; (iii) the 6′-GL content is at least 30% by weight of the total GOS in the composition; and (iv) at least 0.5% by weight of the total GOS has a polymerization degree (DP) of six or more. The GOS composition does not trigger GOS-allergy as assessed in a basophil activation test (BAT). | 2021-10-28 |
20210330688 | OLIGOSACCHARIDES COMPOSITION FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME - The present invention relates to the use of a galactooligosaccharide composition for preventing or reducing the risk of developing metabolic syndrome. | 2021-10-28 |
20210330689 | COMPOSITION FOR TREATING BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF - The present invention relates to pharmaceutical compositions for treating blood cancer, which includes 4′-thio-5-aza-2′-deoxycytidine (Aza-T-dCyd), and methods of treating blood cancer using a composition for oral administration that includes Aza-T-dCyd. The present invention provides a significant blood cancer therapeutic effect without having toxicity in a blood cancer mouse model or a human even with the Aza-T-dCyd dose conventionally known to have toxicity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2021-10-28 |
20210330690 | TREATING UNTREATED OR TREATMENT-RESISTANT DIABETES WITH GLUCOKINASE ACTIVATOR AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR - Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator and a sodium-glucose cotransporter-2 inhibitor. | 2021-10-28 |
20210330691 | METHODS OF USING COSMETIC COMPOSITIONS COMPRISING EXOPOLYSACCHARIDES DERIVED FROM MICROBIAL MATS - A skin care composition is disclosed comprising at least one exopolysaccharide (EPS) originating from a microbial mat, the EPS being in a concentration of about 0.001% w/w to about 1.5% w/w of the composition. Uses and methods of use thereof. In specific embodiments, the EPSs are derived from microorganisms isolated from microbial mats found in French Polynesia. The composition is useful in reducing signs of skin aging and environmental damage by altering skin cell metabolism and improving hydration. | 2021-10-28 |
20210330692 | CCR7 APTAMERS AND USES THEREOF - Disclosed herein are CCR7 aptamers that specifically bind to and internalize into CCR7-expressing cells. The aptamers can be used as a therapeutic agent by itself or in combination with a small molecule by forming a conjugate with the small molecule. Targeted delivery of the small molecule can be achieved by such conjugates. Also disclosed are methods of treating a subject suffering from cancer by administering an effective amount of the aptamer or the aptamer-small molecule conjugate to the subject. | 2021-10-28 |
20210330693 | HEPARANASE INHIBITORS AND THEIR USE AS ANTI-CANCER COMPOUNDS - Anti-heparanase compounds for the treatment of cancer are described. The anti-heparanase compounds are high affinity, synthetic glycopolymers that result in minimal anticoagulant activity. Stereoselective fluorinated forms of these compounds are also provided. | 2021-10-28 |
20210330694 | METHOD FOR TREATING DIASTOLIC HEART FAILURE BY INHIBITING GALECTIN-3 - A method for treating diastolic heart failure (heart failure with preserved ejection fraction (HFpEF)) in a subject in need thereof is provided including administering a therapeutically effective amount of a galectin-3 inhibitor to the subject. | 2021-10-28 |
20210330695 | TREATMENT OF PAIN WITH POLYSULFATED POLYSACCHARIDES - The present disclosure relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of pain or pain conditions. In particular, the disclosure relates to use of polysulfated polysaccharides and compositions thereof for the treatment of pain or pain conditions mediated by mature Nerve Growth Factor (NGF) or its precursor pro-Nerve Growth Factor (pro-NGF). | 2021-10-28 |
20210330696 | A HIGH CAPACITY PLATFORM FOR IMMUNOGENIC CANCER CELL DEATH - Compositions comprising, and methods of using, mesoporous hybrid siliceous nanoparticles comprising a TLR ligand or other immune stimulant(s), and an agent to induce immunogenic cell death. | 2021-10-28 |
20210330697 | Method Of Treating Inflammation - The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer. | 2021-10-28 |
20210330698 | METHODS AND COMPOSITIONS FOR INHIBITING ENVELOPED VIRUSES USING LOW MOLECULAR WEIGHT HYDROPHOBICALLY MODIFIED POLYMERS - This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a low molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said composition is substantially free of surfactant having an HLB greater than about 12. | 2021-10-28 |
20210330699 | METHODS OF INHIBITING ENVELOPED VIRUSES USING LOW MOLECULAR WEIGHT HYDROPHOBICALLY MODIFIED POLYMERS - This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a low molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses, wherein said compositions further comprise less than about 9% by weight of surfactant having an HLB of greater than 12. | 2021-10-28 |
20210330700 | METHODS AND COMPOSITIONS FOR INHIBITING INFLUENZA VIRUSES USING LOW MOLECULAR WEIGHT HYDROPHOBICALLY MODIFIED POLYMERS AND POLYALKYLENE GLYCOLS - This invention relates to methods and compositions for inhibiting the transmission of influenza viruses, which entails applying a composition containing a polyalkylene glycol compound to an infectable or ingestible surface that may contain viruses. It further relates to methods and compositions for inhibiting the transmission of influenza and other enveloped viruses, which entails applying a composition containing a polyalkylene glycol compound and a low molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses. | 2021-10-28 |
20210330701 | METHODS AND COMPOSITIONS FOR INHIBITING ENVELOPED VIRUSES USING HIGH MOLECULAR WEIGHT HYDROPHOBICALLY MODIFIED ALKALI SWELLABLE EMULSION POLYMERS AND SURFACTANT - This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a high molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12. | 2021-10-28 |
20210330702 | Tetrathionate for Cyanide and Methylmercaptan Poisoning - Provided is a method, and pharmaceutical composition, to treat or prevent cyanide poisoning and/or methylmercaptan poisoning comprising administering to a subject in need an effective amount of tetrathionate by intramuscular injection or by intranasal administration. Also provided is a method for detecting the presence of tetrathionate in a sample by reacting it with cyanide and measuring the resulting thiocyanate with ferric nitrate. | 2021-10-28 |
20210330703 | SELENIUM DISULFIDE COMPOSITIONS FOR USE IN TREATING MEIBOMIAN GLAND DYSFUNCTION - Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates. | 2021-10-28 |
20210330704 | Nasal Spray Composition - Compositions and methods for treating and preventing respiratory symptoms related to viral and bacterial infections are described. The composition includes water, ionic minerals, trace minerals, a niacin-related compound, and an optional ingredient. The optional ingredient is mastic gum, a prebiotic, or both. The niacin-related compound is methyl nicotinate, nicotinic acid, nicotinamide, niacin, or a combination of two or more of the foregoing. The method involves nasal, auricular, or oral administration or a combination of two or more of the foregoing routes of administration to a human or other mammal. | 2021-10-28 |
20210330705 | TOLEROGENIC DENDRITIC CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME - Disclosed are compositions of matter, cells, and therapeutic protocols useful for treatment of acute respiratory distress syndrome (ARDS). In some embodiments the invention teaches treatment of ARDS caused by viruses including COVID-19 through administration of an immature population of dendritic cells at a concentration and frequency to inhibit pulmonary inflammation, alveolar leakage, and loss of pulmonary function. In some embodiments immature dendritic cells are generated by culture of autologous and/or allogeneic monocytes with IL-4 and GM-CSF without a maturation step. In other embodiments, generation of immature dendritic cells is performed by administration on NF-kappa B inhibitors. In other embodiments dendritic cells are utilized in an immature form to stimulate generation of T regulatory cells. | 2021-10-28 |
20210330706 | Children Blood Transfusion and Thymus Hormonal Therapy as Antiviral and Antibacterial Compounds - The present invention describes compounds that are safe, nontoxic, noncorrosive, and nonirritating and methods thereof that are antibacterial and antiviral (encompassing cancer as well or chemotherapy) for the prevention and treatment of individuals suffering from infectious diseases. The compounds of the instant invention can also be administered to those individuals who are in need of such therapy such as those who have thymus diseases or those who are old enough that the thymus gland does not function anymore (thymus involution). This method can also be employed in healthy subjects as a preventive measure against such infections. The method relies on administering to infected patient healthy whole blood or healthy plasma transfusion procured from healthy children where it is permissible by law (emphasis added) or from healthy adults ages 18 to 20 years. This as a result will endogenously regenerate the thymus gland via the process of thymopoiesis to produce mature T cells, which are the most important cells in adaptive immunity for combating bacterial and viral infections. The compounds of the instant invention can be those, but not limited to, hormones secreted by the thymus gland and their synthetic counterparts, a combination of them, their active compounds, their progenitors, and their stimulating and mediated compounds and their mixtures thereof all can be used in the instant invention. | 2021-10-28 |
20210330707 | HIGHLY ACTIVE NK CELL AND USE THEREOF - An NK cell showing higher cytotoxic activity is provided. An object of the present invention is to provide a pharmaceutical composition for NK cell therapies expected to be highly effective. The present invention provides an NK cell having the following characteristics of (1) and (2) or a population thereof. (1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative, and (2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive. The present invention also provides a pharmaceutical composition containing a population of such NK cells, and a therapeutically effective amount of antibodies. | 2021-10-28 |
20210330708 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-10-28 |
20210330709 | CELL PREPARATION FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO - The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. | 2021-10-28 |
20210330710 | INFLAMMATORY CYTOKINE PRODUCTION INHIBITOR - Provided are inflammatory cytokine production inhibitors which inhibit the production of the inflammatory cytokines TNF-α and IL-1β and can be applied to drugs effective against inflammatory diseases caused by overproduction of these inflammatory cytokines, such as chronic inflammation (e.g., rheumatoid arthritis, ulcerative colitis) and Crohn's disease, as well as type 2 diabetes, depression, obesity, sepsis, atherosclerosis, dermatitis, dementia, schizophrenia, and Parkinson's disease, and also to foods and drinks such as health foods. The inflammatory cytokine production inhibitors contain as an active ingredient an enzyme-treated whey obtained by contacting whey with β-galactosidase. The enzyme-treated whey is obtained by further contacting with sialidase. | 2021-10-28 |
20210330711 | COMPOSITIONS WITH ANTIVIRAL ACTIVITY AND RELATED METHODS - Compositions that include extracellular matrix (ECM) materials having antiviral activity and methods of use thereof are disclosed. The compositions may be administered to a subject in need thereof, e.g., subject having a viral infection or being suspected of having a viral infection. The virus may be an enveloped virus, such as a coronavirus. | 2021-10-28 |
20210330712 | USE OF ANTI-AGING GLYCOPROTEIN FOR ENHANCING SURVIVAL OF NEUROSENSORY PRECURSOR CELLS - The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate thereof: | 2021-10-28 |
20210330713 | HUMAN HEPATOCYTES AND USES THEREOF - Disclosed herein are human hepatocytes for example isolated human hepatic progenitor cells, artificial tissue or organ thereof, and kits or compositions thereof. Also disclosed herein are various methods of using a human hepatocyte disclosed herein. | 2021-10-28 |
20210330714 | Placental Membrane Preparations and Methods of Making and Using Same for Regenerating Cartilage and Spinal Intervertebral Discs - A method for treating cartilage defects including providing a placental membrane preparation that comprises ground or minced placental membranes and optionally, a ground or minced cartilage and/or biocompatible glue, and introducing the preparation to a cartilage defect within a skeletal joint. The cartilage defect may comprise a hyaline cartilage defect, such as a chondral defect, or meniscal defect. The treatment may be provided in combination with other treatments such as marrow stimulation treatments and surgical repair treatments using sutures or other fixation techniques. The preparation promotes the regeneration of cartilage within the skeletal joint. | 2021-10-28 |
20210330715 | ANTI-BIOFILM AGENTS AND USES THEREOF - The present disclosure relates to amoebae (slime molds) and uses thereof. In particular, the present disclosure relates to anti-biofilm components of amoebae to target biofilms. | 2021-10-28 |
20210330716 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation. | 2021-10-28 |
20210330717 | Methods for Treating Ulcerative Colitis - The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method. | 2021-10-28 |
20210330718 | COMPOSITION AND METHODS FOR TREATING CANCER AND IMMUNE DISORDERS USING VEILLONELLA BACTERIA - Provided herein are methods and compositions related to | 2021-10-28 |
20210330719 | PROBIOTIC COMBINATION FOR TREATMENT OF INFLAMMATORY-RELATED GASTROINTESTINAL DISORDERS - Disclosed is a probiotic combination comprising | 2021-10-28 |
20210330720 | COMPOSITION AND METHODS FOR MICROBIOTA THERAPY - The present invention provides a composition comprising a co-culture of at least two distinct bacterial families, having differing growth and/or proliferative conditions. In some embodiments, the composition comprises a plurality of bacterial genera with high similarity to microbial flora. | 2021-10-28 |
20210330721 | HIGH POTENCY STABLE FORMULATIONS OF VAGINAL LACTOBACILLUS - This invention provides for a dry preserved formulation of | 2021-10-28 |
20210330722 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION - The present disclosure relates to bacteriophages and compositions capable of infecting and killing | 2021-10-28 |
20210330723 | SUPPLEMENT FOR MITIGATING WOMAN'S DISORDERS CAUSED BY AGEING - Combination of dry extract of Rhodiola, dry extract of Tribulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing. | 2021-10-28 |